Intravenous pegloticase market?

Q: Intravenous pegloticase market?

What’s the size of the IV pegloticase market today? In 2023 the global market for IV pegloticase—sold under the brand name Krystexxa—was estimated at roughly USD 400 million, with the U.S. accounting for about 55 % of sales. The segment is expected to grow at a CAGR of 7–9 % through 2030, driven by a rising prevalence of severe refractory gout and limited alternative biologics. [1] Who makes and distributes IV pegloticase? Pfizer is the sole manufacturer of Krystexxa. The drug is sold exclusively through specialty pharmacies that coordinate with infusion centers. Pfizer also manages the U.S. reimbursement program under a “single‑dose” model, while international licensing partners supply the drug in other regions. [2] How much does a single IV dose cost?

Question

Accepted Answer

What’s the size of the IV pegloticase market today?
In 2023 the global market for IV pegloticase—sold under the brand name Krystexxa—was estimated at roughly USD 400 million, with the U.S. accounting for about 55 % of sales. The segment is expected to grow at a CAGR of 7–9 % through 2030, driven by a rising prevalence of severe refractory gout and limited alternative biologics. [1]

Who makes and distributes IV pegloticase?
Pfizer is the sole manufacturer of Krystexxa. The drug is sold exclusively through specialty pharmacies that coordinate with infusion centers. Pfizer also manages the U.S. reimbursement program under a “single‑dose” model, while international licensing partners supply the drug in other regions. [2]

How much does a single IV dose cost?

Ask Questions, Get Industry Insights … Instantly

Recent Questions

Intravenous pegloticase market?